Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fudan University
The standard treatment in patients with refractory or relapsed diffuse large B-cell lymphoma is salvage chemotherapy followed by autologous transplantation for responsive patients. However, the standard of salvage chemotherapy remains uncertain. This study is to evaluate the efficacy and safety of R-ESHAP regimen in a multi-center basis.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age range: 18-65 years old
Histological confirmed diffuse large B-cell lymphoma
Refractory or first relapsed disease
Prior anthracycline exposure
Measurable disease
ECOG performance status 0-1
Life expectancy of more than 3 months
Bone marrow function: ANC≧1.5×109/L, PLT≧100×109/L, Hb≧90g/L
Liver function: total bilirubin, ALT and AST \<1.5×UNL
Renal function: Cr\<1.5×UNL, CCR≧50ml/min
No contraindication for transplantation
You may not be if
Evidence of CNS and bone marrow involvement
More than 1 type of chemotherapy regimens exposure
High level of HBV DNA
Contraindication of high-dose methylprednisolone
Pregnant or lactating women
History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix
History of allergic reaction/hypersensitivity to rituximab
